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Abstract The three mammalian tachykinins, substance P (SP),
neurokinin A (NKA) and neurokinin B (NKB), exert their
physiological effects through specific receptors, NK1, NK2 and
NK3, respectively. However, homologous binding studies have
recently demonstrated that, contrary to the generally accepted
belief, NKA could bind NK1 receptor with high affinity (Hastrup
and Schwartz, 1996). Using COS-7 cells expressing the human
NK1 receptor, we show that two simultaneous point mutations
(E193L and V195R) in a restricted five amino acid sequence (the
(193^197) region), selected because of its hydropathic comple-
mentarity with the common C-terminal extremity of tachykinins,
abolish both the high-affinity binding and highly potent biological
activity of NKA, without affecting those of SP. In addition, the
same mutations also suppressed the high functional activity of
septide, a synthetic SP atypical agonist ([pGlu6-Pro9] SP 6^11).
These results suggest that the (193^197) region, located at the
end of the second extracellular loop of the receptor, could be part
of a common high-affinity binding domain for both NKA and
septide, distinct from the SP binding site.
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1. Introduction
The three main mammalian tachykinins, substance P (SP),
neurokinin A (NKA) and neurokinin B (NKB), exert their
various biological e¡ects (e.g. nociception, control of smooth
muscle activity and exocrine secretion, in£ammation and im-
munomodulation) through interactions with three di¡erent
receptors, named NK1, NK2 and NK3 [1], which belong to
the G protein-coupled seven transmembrane domain receptor
family [2]. It has been generally admitted for more than ten
years that, despite some degree of cross-reactivity, SP is the
natural endogenous ligand for the NK1 receptor, NKA for
the NK2 receptor, and NKB for the NK3 receptor. However,
as recently reviewed [3], it has also been recognized for a long
time that some observations did not ¢t with this classical
‘three-peptide-three-receptor dogma’. Examples include the
¢nding that NKA can behave as a potent agonist in func-
tional assays considered to be speci¢c for the NK1 receptor
[4,5], or the observation that NKA can exert in vivo physio-
logical actions without identi¢ed NK2 receptors on target
cells, especially in the central nervous system [6]. In fact, it
has been clearly demonstrated in CHO cells expressing only
the recombinant NK1 receptor [7], that NKA could indeed
induce a potent pharmacological e¡ect at nanomolar concen-
trations, although surprisingly, its apparent a⁄nity estimated
through its ability to displace radiolabeled SP in competition
binding experiments was rather low (in the micromolar
range). Recently, however, Hastrup and Schwartz [8], also
working on recombinant receptor-expressing cells, reported
for the ¢rst time that NKA is actually a high-a⁄nity ligand
for the NK1 receptor. This was established from homologous
binding analysis, i.e. by using radioactive NKA directly, in-
stead of studying the indirect e¡ect of this tachykinin on the
binding of labeled SP. So, the question now under debate
concerns the precise location of this site for NKA on the
NK1 receptor, namely do NKA and SP bind to the same or
distinct sites? If the latter hypothesis is correct, it might in
theory be possible to ¢nd region(s) in the NK1 recombinant
receptor in which mutations would a¡ect the binding of one
tachykinin without changing the binding of the other one. The
aim of this paper was to investigate this possibility.
In order to orient the search for such a region, we decided
to follow a molecular recognition theory stating that peptides
or proteins can interact through amino acid sequences dis-
playing inverse hydropathic pro¢les [9]. More than 40 exam-
ples of ligand characterization based on complementary hy-
dropathy have been reported in the literature [10]. In the ¢eld
of antigen-antibody interactions, we recently illustrated this
theory by demonstrating, using surface plasmon resonance
technology, the importance of hydropathic complementarity
for the kinetic parameters of peptide-antibody binding [11]. In
terms of biological receptors, the search for hydropathically
opposed sequences by means of computer programs has al-
ready been used successfully to identify the putative binding
sites for a dozen ligands (reviewed in [12]) and, very recently,
complementary hydropathy has even served to identify a nov-
el prion protein receptor [13].
In the present study, we report the occurrence in the human
NK1 receptor of four sequences whose hydropathic pro¢les
are opposed to that of the common C-terminal sequence of
tachykinins, this C-terminal extremity having long been
known to be directly involved in receptor binding. We show
that two point mutations, simultaneously performed in one of
these sequences (the (193^197) region) in order to suppress the
hydropathic complementarity with tachykinin agonists, re-
sulted in a nearly complete loss in the direct binding of radio-
labeled NKA without signi¢cantly a¡ecting that of labeled
SP. Accordingly, these mutations largely impaired the highly
potent pharmacological e¡ect of NKA without changing that
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of SP. In addition, we observed that the same mutations in
the (193^197) region also abolished the pharmacological ac-
tion of septide, a synthetic C-terminal SP analog ([pGlu6-
Pro9] SP 6^11). Although this compound has long been con-
sidered as a potent and selective agonist of the NK1 receptor
[14], its atypical pharmacological and binding properties [7,15]
have led some authors to postulate more recently the existence
of a speci¢c ‘septide-sensitive’ receptor (review in [16]).
Taken together, our results support the hypothesis of the
existence of two distinct high-a⁄nity binding sites on the NK1
receptor, one for SP and the other for both NKA and septide,
this latter site being at least in part located at the distal ex-
tremity of the second extracellular loop.
2. Materials and methods
2.1. Materials
125I-substance P (74 TBq/mmol), 125I-NKA (74 Tbq/mmol) and
myo-[2-3H]inositol (651 Gbq/mmol) were from Amersham France.
Non-labeled peptides were from Neosystem (Strasbourg, France).
Cell culture medium Ham F-12, fetal calf serum, HEPES, penicillin,
streptomycin were from GIBCO (Eregny, France). Bacitracin, lithium
chloride (LiCl) and bovine serum albumin (BSA) were from Sigma.
Cell culture plastic dishes were from NUNC (Roskilde, Denmark).
2.2. Determination of hydropathically opposed sequences in the human
NK1 receptor and tachykinin agonists
In order to identify in the human NK1 receptor putative interaction
sites with SP, NKA and septide, we used a computer program which
we described recently [17]. This software selects amino acid sequences
of at least ¢ve amino acids whose hydropathic pro¢les are opposed in
the two molecules to be compared, i.e. here the NK1 receptor on the
one hand and the C-terminal extremities of SP, NKA and septide, on
the other hand. This opposition is quantitatively estimated through
the calculation of linear regression analysis of hydropathic values
(taken from the Kyte and Doolittle scale) for a given position in
each sequence: a correlation coe⁄cient (r) between 30.8 and 31
was imposed as re£ecting a high degree of opposition.
2.3. Human NK1 receptor mutagenesis
The cDNA clone of the human NK1 receptor in pCDM8 was a
generous gift from Dr. N.P. Gerard (Harvard Medical School, Bos-
ton, USA). In order to abolish the hydropathic complementarity be-
tween the (193^197) NK1 sequence and tachykinin agonists, we chose
to replace at the same time two amino acids by residues with opposite
hydropathic values, i.e. Glu193 (33.5) by Leu (+3.7) and Val195 (+4.2)
by Arg (34.5). Mutagenesis was realized using the PCR site-directed
mutagenesis system (BRL/Life Technologies) according to the speci¢-
cations of the supplier. Sequences of mutagenic oligonucleotides used
for NK1 receptor mutant, i.e. E193L and V195R, are AUU UAU
UUG AAA CGU UAC CAC AUC UGT GTG ACT GTG CTG
ATC TAC TTC CTC CCC and GAU GUG GUA ACG TTT
CAA AUA AAU CTT GTT CGG (the modi¢ed amino acids are
encoded by the underlined sequences). Wild-type or mutant receptors
were subcloned at XhoI-EcoRI in pcDNA3 (in Vitrogen). Sequences
were checked using the dideoxy termination method.
2.4. Cell culture and transfection
COS-7 cells were cultured in Dulbecco’s modi¢ed Eagle’s medium
supplemented with 10% fetal calf serum, 2 mM glutamine, 100 units/
ml penicillin and 100 Wg/ml streptomycin at 37‡C in a humidi¢ed
atmosphere of 5% CO2. The pcDNA3 construct harboring the human
NK1 receptor cDNA modi¢ed and non-modi¢ed sequence was trans-
fected into COS-7 cells by electroporation. Control sham transfections
were performed with the same expression vector alone.
2.5. Binding assays
Direct binding analysis was performed as described previously [7].
In brief, COS-7 cells (105/well) were incubated for 100 min in the
presence of 0.01 to 10 nM of isotopic dilutions of [125I]-SP or [125I]-
NKA. Non-speci¢c binding was determined in the presence of 1 WM
SP or NKA. Experimental data were analyzed using the computer
program LIGAND.
2.6. Measurements of phosphatidylinositol hydrolysis
Experiments were carried out following a standard protocol already
described in details [7]. Brie£y, after labeling with [3H]inositol for 24
h, COS-7 cells (105/well) were incubated for 30 min at 37‡C in the
presence of tachykinin agonists. Incubations were terminated by lys-
ing cells with Triton X-100 and [3H]inositol phosphates were sepa-
rated by chromatography of the aqueous phase recovered after addi-
tion of a chloroform/methanol (1:2) mixture.
3. Results
3.1. Occurrence of hydropathically opposed sequences in the
human NK1 receptor and tachykinin agonists
Applying the restrictive parameters of the computer pro-
gram described in Section 2, four sequences were identi¢ed
in the NK1 receptor on the basis of hydropathic complemen-
tarity with the C-terminal extremity of tachykinins: the (13^
17) and (20^26) sequences, located in the N-terminal extra-
cellular extremity, the (136^140) sequence in the second intra-
cytoplasmic loop, and the (193^197) sequence at the extremity
of the second extracellular loop. For example, the (20^26)
sequence (Fig. 1) was best hydropathically opposed (not
shown) with the C-terminal extremity of SP (r =30.94 over
a stretch of seven amino acids), while the (193^197) sequence
appeared best opposed (Fig. 1) to those of NKA and septide
(r =30.81 and 30.84, respectively). We chose this latter re-
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Fig. 1. Structure of the human NK1 receptor for substance P with
two sequences identi¢ed on the basis of hydropathic complementar-
ity with the common C-terminal extremity of tachykinins: the
SEPNQFV (20^26) sequence and the EKVYH (193^197) sequence
(upper panel). The hydropathic pro¢le of the EKVYH (193^197) re-
ceptor sequence is compared with those of NKA (6^10): FVGLM
and septide (2^6): FFPLM (lower panel). The hydropathic pro¢le
of the (E193L, V195R) mutant (193^197) sequence is also indicated
(dotted line).
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gion for further analysis by means of site-directed mutagenesis
since it was located in the second extracellular loop, i.e. a
region shown to be often involved in the binding of various
ligands on 7TM receptors [18]. As shown in Fig. 1, the two
simultaneous mutations E193L and V195R introduced in this
region abolished the hydropathic complementarity with the C-
terminal extremity of NKA and septide (r = +0.28 and +0.61,
respectively, in the double mutant receptor).
3.2. E¡ects of point mutations in the (193^197) sequence of the
human NK1 receptor on the direct binding of radiolabeled
SP and NKA
Saturation binding experiments showed that labeled SP
(Fig. 2A) was able to bind both wild-type and mutant NK1
receptor with a similar high a⁄nity (Kd = 0.12 þ 0.02 versus
0.18 þ 0.02 nM, respectively). Moreover, identical maximal
binding values were found for SP on wild-type and mutant
receptors (Bmax = 5.98 þ 0.76 and 6.00 þ 0.18 fmole/mg protein,
respectively, which corresponds to about 22 000 binding sites/
cell). These results indicate that mutations in the (193^197)
region of the NK1 receptor did not signi¢cantly a¡ect either
the expression level of recombinant receptors on cell mem-
branes, or the binding a⁄nity of SP for these receptors. By
contrast, mutations largely impaired the binding of labeled
NKA (Fig. 2B). Indeed, whereas NKA appeared to bind
wild-type NK1 receptor with a high a⁄nity (Kd = 0.16 þ 0.02
nM), its binding on mutant receptor was almost totally abol-
ished, at least for concentrations up to 1038 M. On wild-type
receptor, the maximal binding capacity of labeled NKA was
estimated as 2.21 þ 0.06 fmole/mg protein (8100 binding sites/
cell), a Bmax value amounting to about 37.0 þ 1.0% of that
found for SP.
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Fig. 3. Inositol phosphate (IP) production as a function of the con-
centration of tachykinin ligands in COS-7 cells expressing wild-type
(a) or (E193L, V195R) mutant (R) NK1 receptors. Cells were incu-
bated in the presence of increasing concentrations of SP (A), NKA
(B) or septide (C). Basal level of IP production was determined in
wells to which no agonist was added. Results are the mean þ S.D.
of four independent experiments done in triplicate. They are ex-
pressed as percent of maximal response for each agonist on wild-
type receptor-expressing cells. Similar absolute values were obtained
using saturating concentrations of SP, NKA and septide on wild-
type receptor-expressing cells.
Fig. 2. Saturation analysis of the binding of labeled SP (A) and la-
beled NKA (B) to COS-7 cells expressing wild-type (a) or (E193L,
V195R) mutant (R) NK1 receptors. Cells were incubated in the
presence of increasing concentrations of isotopic dilutions of 125I-SP
or 125I-NKA (10 to 10 000 pM). Non-speci¢c binding was deter-
mined in the presence of 1 WM unlabeled SP or NKA, respectively.
Results are the mean þ S.D. of two independent experiments done in
triplicate. Inset: Scatchard analysis of the data.
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3.3. E¡ects of point mutations in the (193^197) sequence of the
human NK1 receptor on biological activity of SP, NKA
and septide
As shown in Fig. 3, SP, NKA and septide were highly
potent in inducing inositol phosphate formation in COS-7
cells expressing the wild-type receptor, with EC50 values of
0.47 þ 0.22, 4.78 þ 1.70 and 1.85 þ 0.78 nM, respectively, con-
¢rming earlier reports [7]. In contrast, in COS-7 cells bearing
NK1 receptors with mutations in the (193^197) region (ex-
pressed at a level similar to that found in the wild-type recep-
tor-bearing cells, see above), we found that the high potency
of both NKA (Fig. 3B) and septide (Fig. 3C) in inducing a
biological response was abolished (EC50s 1 WM), whereas
that of SP (Fig. 3A) was little a¡ected (EC50 = 2.30 þ 1.20
versus 0.47 þ 0.22 nM for the wild-type receptor-expressing
cells). In addition, we checked in control experiments that
the di¡erences in the amount of inositol phosphate production
induced by NKA or septide in wild-type and mutant NK1
receptor-expressing cells were not related to experimental con-
ditions such as the incubation time (30 min) in the presence of
agonists, since similar values were obtained when using longer
incubation periods, up to 2 h (results not shown).
4. Discussion
The data presented here point to the importance of a short
sequence, the (193^197) region in the human NK1 receptor
(located at the end of the second extracellular loop), in the
high-a⁄nity binding of NKA, but not of SP, and in the spe-
ci¢c triggering of its biological response. They constitute the
¢rst report, to our knowledge, of point mutations which a¡ect
di¡erently the true a⁄nities (measured in homologous binding
experiments) of two di¡erent endogenous tachykinins for the
same receptor.
The hydropathic complementarity methodology used here
to guide the search for putative interactive sequences in the
NK1 receptor has been successfully employed in recent years
to identify ligand binding domains in a large variety of pro-
teins, including enzymes, antibodies, MHC proteins and bio-
logical receptors (see [19] for a review). Although our present
study was focused on the (193^197) region of the NK1 recep-
tor, it might be no coincidence that the (20^26) extracellular
sequence (Fig. 1), also identi¢ed here on the basis of hydro-
pathic complementarity with the common C-terminal extrem-
ity of tachykinins, very precisely corresponds to a region
which has been already shown by Fong et al. [20,21] to play
a major role in the high-a⁄nity binding of the C-terminal part
of SP. Together with our present results concerning the (193^
197) region, these data from other groups could appear to
lend additional support to this methodology based on hydro-
pathic complementarity.
The ¢nding that the same mutations in the (193^197) region
of the NK1 receptor abolish the potent pharmacological ef-
fects of both NKA and a tachykinin-like peptide, the septide,
strongly suggests that this region would be part of a common
high-a⁄nity binding site for both agonists. This would be in
close agreement with the recent study by Hastrup and
Schwartz [8] showing, for the ¢rst time, that both radiolabeled
peptides bound to the NK1 receptor with similar high a⁄nity
in homologous binding assays as well as in competition
against each other. The existence of a common NKA/septide
binding site would also readily explain why both peptides
exert identical pharmacological e¡ects on cell lines expressing
the recombinant NK1 receptor, and have been said to belong
to the ‘septide-like’ peptide family, triggering the phospho-
lipase C transduction pathway, as opposed to SP and other
‘SP family’ peptides, inducing both the phospholipase C and
the adenylyl cyclase pathways [7].
More importantly, our results strengthen the hypothesis
that this NKA/septide site, involving the (193^197) region, is
distinct from the SP binding site, possibly located at least in
part around the (20^26) region, as discussed above. Alterna-
tively, it could be inferred from our present results that the
mutations in the second extracellular loop would alter the
conformation of a unique tachykinin site, rendering this
area unable to accommodate NKA and septide, but preserv-
ing its SP binding capability. However, to our mind, this ex-
planation seems rather unlikely when considering the results
of numerous directed mutagenesis experiments [20^23] involv-
ing hybrid, chimeric or locally mutated recombinant recep-
tors, which indicate that the binding site of SP is at least
partially located on the extracellular N-terminal part of the
receptor, while that of septide is indeed extending rather in the
C-terminal domain. The actual presence of two distinct SP
and NKA/septide binding sites on the NK1 receptor would
also ¢t well with the observations that some non-peptide SP
antagonists (like RP 67580) behave competitively for SP but
non-competitively for NKA and/or septide [7,15,24], whereas
conversely, other non-peptide antagonists (like CP 96345) are
more potent in antagonizing septide- than SP-induced re-
sponses [25]. In this context, it is noteworthy that it has
been clearly shown by mutational analysis [26] that CP
96345 (unlike SP and RP 67580) binds in the vicinity of the
E193 and H197 amino acids, i.e. precisely in the (193^197)
region that we suggest here to be part of the NKA/septide
binding site. Since this region has been also proposed by the
same authors [27] to play a major role in regulating receptor
conformation, it would be of great interest to re-examine the
homologous as well as the heterologous binding properties of
tachykinin agonists on the several mutant receptors that have
been already engineered.
As regards the current receptor models, it seems likely that
the NK1 receptor could assume at least two conformations in
equilibrium in the membrane, an ‘SP-preferring’ and a ‘gen-
eral tachykinin’ conformer [3]. Our ¢nding that the Bmax value
for NKA was almost three times lower than that for SP con-
¢rms previous data from other groups [8,28] and is in good
agreement with this model, stating in addition that the inter-
conversion between the conformers occurs readily upon SP
binding, but with much more di⁄culty upon NKA or septide
binding [3]. Consequently, a model in which the NK1 receptor
has two active conformers, each one bearing two distinct
binding sites for SP and NKA/septide, appears highly consis-
tent with our present data and also with most of the pharma-
cological and biochemical properties of tachykinin peptides,
including septide.
Finally, we should emphasize that, as discussed recently by
Colquhoun [29], the interpretation of the e¡ects of mutations
on G protein-coupled receptors is never unambiguous. For
instance, our results do not exclude that mutations in the
(193^197) region might a¡ect the allosteric transition or dis-
tribution between the two receptor conformers, as described
for other mutations in the NK1 receptor [30]. In this context,
photoa⁄nity labeling experiments could a¡ord novel insights
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into the location of tachykinin binding domain(s). However,
since ligand binding sites very probably correspond to di¡er-
ent receptor areas scattered all along the primary sequence, it
is not surprising that amino acids located outside the (193^
197) or (20^26) regions have already been implicated in the
high-a⁄nity binding of agonists [31,32].
In conclusion, regardless of whether or not it was chance
that allowed us to identify the (193^197) sequence, the ¢nding
on the NK1 receptor of a restricted region speci¢cally in-
volved in the in vitro pharmacological action of NKA
strengthens the physiological importance of this endogenous
tachykinin, co-released in vivo with SP, in triggering speci¢c
responses through NK1 receptors and/or in modulating the
SP-induced responses. In addition, this newly identi¢ed ex-
tracellular region in the NK1 receptor may now appear as
an original pharmacological target for development of novel
selective bioactive compounds.
Acknowledgements: This work was supported by ‘Le Commissariat aØ
l’Energie Atomique’ (CEA, France) and the ‘MinisteØre de l’Education
Nationale, de l’Enseignement SupeŁrieur et de la Recherche’ (ME-
NESR, JE 2158, UniversiteŁ Paris 7-Denis Diderot). The authors are
greatly indebted to Dr. Norma P. Gerard (Harvard Medical School,
Boston, USA) for the generous gift of the cDNA coding for the
human NK1 receptor. We also gratefully acknowledge Drs. S. Sagan,
S. Lavielle and G. Chassaing (URA CNRS 493, Paris) for helpful
discussions and suggestions.
References
[1] Regoli, D., Boudon, A. and Fauchere, J.L. (1994) Pharmacol.
Rev. 46, 551^599.
[2] Gerard, N.P., Bao, L., Xioa-Ping, H. and Gerard, C. (1993)
Regul. Pept. 43, 21^35.
[3] Maggi, C.A. and Schwartz, T.N. (1997) Trends Pharmacol. Sci.
18, 351^354.
[4] Yanagisawa, M. and Otsuka, M. (1990) Br. J. Pharmacol. 100,
711^716.
[5] Maggi, C.A., Patachini, R., Quartara, L., Rovero, P. and Santi-
cioli, P. (1991) Eur. J. Pharmacol. 197, 167^174.
[6] Otsuka, M. and Yoshioka, K. (1993) Physiol. Rev. 73, 229^
307.
[7] Sagan, S., Chassaing, G., Pradier, L. and Lavielle, S. (1996)
J. Pharm. Exp. Ther. 276, 1039^1048.
[8] Hastrup, H. and Schwartz, T.W. (1996) FEBS Lett. 399, 264^
266.
[9] Bost, K.L. and Blalock, J.E. (1989) Methods Enzymol. 168, 16^
28.
[10] Baranyi, L., Campbell, W., Ohshima, K., Fujimoto, S., Boros,
M. and Pkada, H. (1995) Nature Med. 1, 894^901.
[11] Hanin, V., DeŁry, O., Boquet, D., Sagot, M.A., CreŁminon, C.,
Couraud, J.Y. and Grassi, J. (1997) Mol. Immunol. 34, 829^838.
[12] Fassina, G. and Melli, M. (1994) ImmunoMethods 5, 114^120.
[13] Martins, V.R., Graner, E., Garcia-Abreu, J., De Souza, S.J.,
Mercadantf, A.F., Veiga, S.S., Zanata, S.M., Neto, V.M. and
Brentani, R.R. (1997) Nature Med. 3, 1376^1382.
[14] Wormser, U., Laufer, R., Hart, Y., Chorev, M., Gilon, C. and
Selinger, Z. (1986) EMBO J. 5, 2805^2808.
[15] Pradier, L., MeŁnager, J., Le Guern, J., Bock, M.D., Heuillet, E.,
Fardin, V., Garret, C., Doble, A. and Mayaux, J.F. (1994) Mol.
Pharmacol. 45, 287^293.
[16] Glowinski, J. (1995) Trends Pharmacol. Sci. 16, 365^367.
[17] Boquet, D., DeŁry, O., Frobert, Y., Grassi, J. and Couraud, J.Y.
(1995) Mol. Immunol. 32, 303^308.
[18] Hoebeke, J. (1995) MeŁdecine/Sciences 12, 1661^1667.
[19] McGuigan, J.E. (1994) ImmunoMethods 5, 158^166.
[20] Fong, T.M., Yu, H., Huang, R.R.C. and Strader, C.D. (1992)
Biochemistry 31, 11806^11811.
[21] Fong, T.M., Huang, R.R.C. and Strader, C.D. (1992) J. Biol.
Chem. 267, 25664^25667.
[22] Gether, U., Johansen, T.E., Snider, R.M., Lowe, J.A., Edmonds-
Alt, X., Yokota, Y., Nakanishi, S. and Schwartz, T.W. (1993)
Regul. Pept. 46, 49^58.
[23] Tian, Y., Wu, L.H., Pu, Y., Huang, C.C. and Chung, F.Z. (1996)
J. Neurochem. 67, 1191^1199.
[24] Huleux, C., Berthier, A., Rossignol, B. and Dreux, C. (1998)
J. Neurochem. 70, 858^864.
[25] Maggi, C.A., Patacchini, R., Meini, S. and Guiliani, S. (1993)
Eur. J. Pharmacol. 235, 309^311.
[26] Gether, U., Johansen, T.E., Snider, R.M., Lowe III, J.A., Naka-
nishi, S. and Schwartz, T.W. (1993) Nature 362, 345^348.
[27] Elling, C.E., Nielsen, S.M. and Schwartz, T.W. (1995) Nature
374, 74^77.
[28] Sagan, S., Beaujouan, J.C., Torrens, Y., Sa¡roy, M., Chassaing,
G., Glowinski, J. and Lavielle, S. (1997) Mol. Pharmacol. 52,
120^127.
[29] Colquhoun, D. (1998) Br. J. Pharmacol. 125, 924^947.
[30] Ciucci, A., Palma, C., Manzini, S. and Werge, T.M. (1998) Br. J.
Pharmacol. 125, 393^401.
[31] Yokota, Y., Akazawa, C., Ohkubo, H. and Nakanishi, S. (1992)
EMBO J. 11, 3585^3591.
[32] Boyd, N.D., Kage, R., Dumas, J.J., Krause, J.E. and Leeman,
S.E. (1996) Proc. Natl. Acad. Sci. USA 93, 433^437.
FEBS 21766 22-3-99
A. Wijkhuisen et al./FEBS Letters 447 (1999) 155^159 159
